Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Gutman

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
The Journal of Biological Chemistry|August 31, 2016
Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem CellsShanshan Pei, Mohammad Minhajuddin, Angelo D'Alessandro, et al.
American Journal of Hematology|February 13, 2026
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid LeukemiaMichael K Jones, Jesse Sanchez, Megan Connor, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 20, 2015
De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissueKathleen M Gavin, Jonathan A Gutman, Wendy M Kohrt, et al.
Eclinicalmedicine|October 27, 2025
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trialDaniel A Pollyea, Brett M Stevens, Diana Abbott, et al.
Blood Advances|October 25, 2019
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemiaAmanda C Winters, Jonathan A Gutman, Enkhtsetseg Purev, et al.
Open Forum Infectious Diseases|February 12, 2021
Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal AgentsMatthew A Miller, Kyle C Molina, Jonathan A Gutman, et al.
The Lancet. Haematology|June 29, 2019
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trialBrenda M Sandmaier, Brian Kornblit, Barry E Storer, et al.
Haematologica|April 13, 2023
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemiaJonathan A Gutman, Amanda Winters, Andrew Kent, et al.
Haematologica|February 26, 2026
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.
Cancer Discovery|January 25, 2020
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaShanshan Pei, Daniel A Pollyea, Annika Gustafson, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The Journal of Biological Chemistry|August 31, 2016
Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem CellsShanshan Pei, Mohammad Minhajuddin, Angelo D'Alessandro, et al.
American Journal of Hematology|February 13, 2026
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid LeukemiaMichael K Jones, Jesse Sanchez, Megan Connor, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 20, 2015
De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissueKathleen M Gavin, Jonathan A Gutman, Wendy M Kohrt, et al.
Eclinicalmedicine|October 27, 2025
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trialDaniel A Pollyea, Brett M Stevens, Diana Abbott, et al.
Blood Advances|October 25, 2019
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemiaAmanda C Winters, Jonathan A Gutman, Enkhtsetseg Purev, et al.
Open Forum Infectious Diseases|February 12, 2021
Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal AgentsMatthew A Miller, Kyle C Molina, Jonathan A Gutman, et al.
The Lancet. Haematology|June 29, 2019
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trialBrenda M Sandmaier, Brian Kornblit, Barry E Storer, et al.
Haematologica|April 13, 2023
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemiaJonathan A Gutman, Amanda Winters, Andrew Kent, et al.
Haematologica|February 26, 2026
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.
Cancer Discovery|January 25, 2020
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaShanshan Pei, Daniel A Pollyea, Annika Gustafson, et al.
Pageof 6